Cerevance’s Phase 3 milestone and fresh funding signal growing momentum for a new way of treating Parkinson’s disease.
Parkinson’s disease has a cruel rhythm to it. A person may wake up feeling relatively steady, able to move through the morning with only minor difficulty. Then, almost without warning, the medication stops cooperating. Hands stiffen, walking slows, speech softens and the body feels as though it has abruptly disconnected from itself.
These stretches are known as “OFF periods,” windows of time when Parkinson’s symptoms break through despite treatment. For millions of patients worldwide, they are among the most disruptive parts of living with the disease, not only because they affect movement, but because they make daily life unpredictable.
That unpredictability is exactly what Boston-based biopharma company Cerevance is now trying to tackle.
The company announced that it has completed enrollment in its pivotal Phase 3 ARISE trial evaluating solengepras, an experimental Parkinson’s therapy that takes a notably different route from most existing drugs. At the same time, the company closed an oversubscribed $20 million Series C financing round, extending its financial runway into mid-2027 [1].
It’s a growing recognition that the future of longevity will depend not only on extending lifespan, but on protecting the small, ordinary functions that make daily life feel livable.
For decades, Parkinson’s treatment has centered around dopamine. Now, the dopamine era may be reaching its limits. Most therapies either replace dopamine, mimic it or help the brain hold onto it longer. The approach has transformed care since levodopa first became widely available in the late 1960s, helping patients regain movement and independence. But the brain is rarely that simple.
Over time, many patients begin cycling between “ON” states, where medication works, and “OFF” states, where symptoms resurface. Some also develop involuntary movements known as dyskinesias, often caused by long-term dopamine-related treatment itself. It becomes a balancing act: enough medication to restore movement, but not so much that the treatment creates new problems.
Solengepras is attempting to sidestep that loop altogether. Rather than targeting dopamine directly, the drug acts on something called the GPR6 receptor, part of a separate signaling network in the brain involved in movement regulation. If dopamine therapies function like repeatedly pressing harder on a failing accelerator pedal, Cerevance’s approach is closer to recalibrating the vehicle’s internal control system itself.
The idea is not necessarily to replace dopamine therapies overnight, but to support them in a way that may reduce those destabilizing daily fluctuations. Importantly, solengepras is designed as a once-daily oral therapy used alongside existing Parkinson’s medications.
“This is a critical moment for Cerevance,” said Craig Thompson, CEO of Cerevance. “In our Phase 2 trial, solengepras demonstrated reduced OFF time and a favorable tolerability profile. With ARISE fully enrolled and our oversubscribed Series C secured with strong support from our existing investors, we are funded through topline data and poised to deliver what could be the first non-dopaminergic therapy to reach patients in decades.”
The company expects topline trial results at the end of the third quarter of 2026.
The financing announcement matters almost as much as the clinical milestone itself. Neurology has historically been one of biotech’s most unforgiving sectors. Brain diseases are extraordinarily difficult to study, clinical trials are expensive, and many high-profile programs have failed in late-stage testing. For years, investors treated the space cautiously.
The mood appears to be changing. Cerevance’s latest funding round drew participation from existing backers including Double Point Ventures, Gates Frontier, Google Ventures, Lightstone Ventures, MQB Partners, SV Health Investors’ Dementia Discovery Fund and UPMC.
What stands out is not simply the amount raised, but the fact that current investors chose to deepen their commitment. In biotech, repeat support often signals that stakeholders believe the underlying science continues to hold up as the stakes get higher.
There is also a broader demographic reality driving renewed interest in neurodegenerative disease. Parkinson’s is now considered the fastest-growing neurological disorder globally, affecting more than 10 million people worldwide. Aging populations mean that number will likely rise sharply over the next two decades.
This is where the story intersects directly with longevity science. Increasingly, researchers and investors are shifting toward a harder question: what kind of years are people actually living? A longer life with severe neurological decline is not the future most people are hoping for. That is why therapies aimed at preserving cognition, mobility and independence are beginning to occupy a more central place in the longevity economy. In many ways, diseases like Parkinson’s are becoming one of the defining tests of whether healthy aging can move from aspiration to reality.
None of this guarantees success. Late-stage Parkinson’s trials remain notoriously difficult, and neuroscience has humbled biotech companies many times before. But the excitement surrounding solengepras reflects a broader shift underway across medicine.
Researchers are beginning to move beyond the idea that aging is simply about wear and tear. Instead, aging is increasingly being understood as a systems-level process – one involving communication breakdowns across cells, networks and organs over time.
That perspective changes how diseases like Parkinson’s are approached. The goal is no longer just helping patients survive longer with disease. It is helping them maintain continuity with themselves: the ability to move through a kitchen without freezing mid-step, hold a conversation without interruption or leave the house without calculating whether medication timing will cooperate.
